<DOC>
	<DOCNO>NCT02858037</DOCNO>
	<brief_summary>HIV Open-label Prevention Extension ( HOPE ) .</brief_summary>
	<brief_title>Trial Assess Continued Safety Adherence Vaginal Ring Containing Dapivirine Women</brief_title>
	<detailed_description>A Phase 3B Open-Label Follow-on Trial Assess Continues Safety Adherence Vaginal ring Containing Dapivirine Women</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women must meet follow criterion eligible inclusion study 1 . Previously enrol MTN020 ( ASPIRE ) 2 . Able willing provide write informed consent screen take part study 3 . Able willing provide adequate locator information , define site SOPs 4 . HIVuninfected base test perform study staff Screening Enrollment 5 . Using effective method contraception Enrollment , intend use effective method duration study participation ; effective method include hormonal method ( except contraceptive ring ) ; intrauterine contraceptive device ( IUCD ) ; sterilization ( participant , define site SOPs ) 6 . At Screening Enrollment , agree participate research study involve drug , medical device , vaginal product , vaccine duration study participation Women meet follow criterion exclude study 1 . Study product use permanently discontinue response AE safety related concern take part MTN020 ( ASPIRE ) trial 2 . Per participant report Screening : 1 . Plans relocate away study site study participation 2 . Plans travel away study site three consecutive month study participation 3 . Per participant report Enrollment , currently take PostExposure Prophylaxis ( PEP ) 4 . With exception MTN020 ( ASPIRE ) , participation research study involve drug , medical device , vaginal product , vaccine , within 60 day enrollment 5 . Is pregnant Screening/Enrollment planning become pregnant participant 's anticipate study participation period 6 . Currently breastfeed 7 . Diagnosed urinary tract infection ( UTI ) , pelvic inflammatory disease ( PID ) , STI reproductive tract infection ( RTI ) require treatment per WHO guideline 8 . At Screening , clinically apparent Grade 3 pelvic exam finding ( observe study staff ) per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) , Addendum 1Female Genital Grading Table Use Microbicide Studies 9 . Has follow laboratory abnormality Screening Visit : 1 . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &gt; Grade 3* 2 . Creatinine &gt; Grade 3* 3 . Hemoglobin &gt; Grade 3* 4 . Platelet count &gt; Grade 3* 5 . Pap result â‰¥ Grade 3 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) 10 . Has significant medical condition condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>